Month: September 2026

The Appointments Add Experience Across Technology, Food and Beverage, Franchising, Branding, and Logistics

BREA, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) — Reborn Coffee Inc. (Nasdaq: REBN) (the “Company”), a leader in the specialty coffee market, today announced the appointment of Edward Park and James Lim to its Board of Directors (the “Board”), effective September 3, 2026.

Mr. Park and Mr. Lim were appointed to fill vacancies on the Board following the Board’s decision to increase its authorized size from seven to eight members. Each director will serve until the Company’s next annual meeting of stockholders or until his successor is duly appointed and qualified, subject to earlier death, resignation, retirement, disqualification, removal from office or other cause.

The appointments broaden the range of operating and industry experience represented on the Board. Mr. Park brings more than 26 years of experience spanning advanced technology and international business management. His background includes senior and leadership roles in the computer and networking industries, including point-of-sale systems, fiber-optic communications, and high-speed networking. Mr. Park also has experience assisting with the development and management of franchise and restaurant businesses. He has served as chief executive officer of multiple companies. Earlier in his career, he held senior positions with Samsung Electronics Co. Ltd, Novell Korea, and Harmonic Inc. Mr. Park holds a Master of Electrical Engineering degree from Seoul National University and has received notable recognition for technology and sales performance during his career.

Mr. Lim brings more than 15 years of experience in coffee distribution, roasting, and branding. After graduating from Kookmin University with a degree in Education, he began his career in the coffee industry with a coffee distribution and roasting company. He subsequently spent more than ten years at Hollys Coffee in Seoul, South Korea, where his responsibilities included coffee distribution, roasting, and branding, followed by approximately five years at Caffe Bene where he served as General Manager. Mr. Lim currently works in the logistics industry in the United States.

Together, the appointments add perspectives spanning brand development, franchise operations, logistics, technology, and international business management. The Company believes this combination of experience will provide additional depth to the Board as it oversees Reborn Coffee’s operations and long-term business priorities.

Neither Mr. Park nor Mr. Lim has been appointed to a committee of the Board at this time, and neither will receive compensation for service as a director.

About Reborn Coffee

Reborn Coffee, Inc. (NASDAQ: REBN) is a California-based specialty coffee retailer focused on delivering high-quality, handcrafted coffee experiences. With a growing global footprint and a dedication to innovation, Reborn is redefining the coffeehouse model through its premium products and technology-forward initiatives.

Forward-Looking Statements

All statements in this release that are not based on historical fact are “forward-looking statements.” While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our recent filings with the Securities and Exchange Commission (“SEC”) including our Form 10-K for the year ended December 31, 2025, which can be found on the SEC’s website at www.sec.gov. Such risks, uncertainties, and other factors include, but are not limited to, the Company’s ability to continue as a going concern, the Company’s ability to successfully open additional locations, the Company’s ability to expand its business both within and outside of California (including as it relates to increasing sales and growing Average Unit Volumes at our existing stores), the degree of customer loyalty to our stores and products, the fluctuation of economic conditions, competition and inflation. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contacts

Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
REBN@mzgroup.us
949-491-8235

Company Contact:
Reborn Coffee, Inc.
ir@reborncoffee.com

New York, New York, Sept. 11, 2026 (GLOBE NEWSWIRE) — Antelope Enterprise Holdings Limited (NASDAQ Capital Market: AEHL) (“Antelope Enterprise”, “AEHL” or the “Company”), which provides livestreaming ecommerce services, business management and information systems consulting services in China, today announced the pricing of a $6.0 million aggregate original principal amount convertible promissory note (the “Note”) to Stratosphere Capital Management Inc. (the “Purchaser”) pursuant to a Note Purchase Agreement entered into on September 9, 2026 (“Issuance Date”).

The Company estimates that the net proceeds from the offering of the Note will be approximately $6.0 million, after deducting estimated offering expenses payable by the Company.

The Note will bear interest at a rate of 8.00% per annum, which will accrue from the Issuance Date until the Note is paid in full, and is payable in cash. The Note has no fixed maturity date and the Note in full or in any portion is convertible into the Company’s Class A ordinary shares, no par value per share, at the option of the holder at any time on or after the Issuance Date. The conversion price will be equal to 80% of the lowest daily volume-weighted average price (VWAP) of the ordinary shares on the Nasdaq Capital Market during the three trading days ending on and including the applicable conversion date.

Conversions of the Note are subject to a strict beneficial ownership limitation, meaning the holder will not have the right to convert any portion of the Note if, immediately following such conversion, the holder and its affiliates would beneficially own in excess of 9.99% of the Company’s issued and outstanding ordinary shares. Additionally, the ordinary shares issuable upon conversion of the Note are subject to a Conversion Shares Registration Cap of 12,000,000 shares.

The Notes are being offered pursuant to a “shelf” registration statement on Form F-3 (File No. 333-295047), that was previously filed by the Company and became effective under the rules of the Securities and Exchange Commission (the “SEC”) on May 5, 2026. A preliminary prospectus supplement relating to the Offering will be filed with the SEC and will be available on the website of the SEC at www.sec.gov. Before investing in the Offering, you should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC, which provide more information about the Company and the Offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. Any unregistered conversion shares issued in excess of the registration cap will constitute “restricted securities” under the Securities Act of 1933, as amended, and may not be offered, sold, or otherwise transferred absent an effective registration statement or an available exemption from registration.

About Antelope Enterprise Holdings Limited

Antelope Enterprise Holdings Limited (“Antelope Enterprise”, “AEHL” or the “Company”) engages holds a 51% ownership position in Hainan Kylin Cloud Services Technology Co. Ltd (“Kylin Cloud”), which operates a livestreaming e-commerce business in China. For more information, please visit our website at https://aehltd.com.

Safe Harbor Statement

Certain of the statements made in this press release are “forward-looking statements” within the meaning and protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause the actual results, performance, capital, ownership or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements in this press release include, without limitation, future Bitcoin market performance and developments in the Bitcoin industry, our ability to regain customers lost resulting in a decline in our revenues, the continued stable macroeconomic environment in the PRC, the consumer and technology sectors continuing to exhibit sound long-term fundamentals, our ability to continue as a going concern, our ability to raise capital to meet our capital needs, and our ability to continue to grow our business management, information system consulting, and online social commerce and live streaming business. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “will,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “point to,” “project,” “could,” “intend,” “target” and other similar words and expressions of the future.

All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties described in our annual report on Form 6-K for the year ended March 31, 2026 and otherwise in our SEC reports and filings. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC’s Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements otherwise are made.

Contact Information:
Antelope Enterprise Holdings Limited
Xiaoying Song, Chief Financial Officer
info@aehltd.com

WFS Investor Relations Inc.
Email: services@wfsir.com
+1 628 283 9214

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) — via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market,” please visit: https://ibn.fm/HOCTP

Today’s multiple sclerosis (“MS”) treatments can slow down disease progression, but none of them halt it outright, and none give back the function patients have already lost. Close to a million people in the United States, and nearly 2.9 million worldwide, live with that reality, watching a condition that steadily chips away at mobility, eyesight and basic physical control.

That gap in treatment options just picked up a serious new contender. Quantum BioPharma Ltd. has received U.S. Food and Drug Administration (“FDA”) clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class candidate designed not to calm the immune system but to shield, and potentially rebuild, the myelin sheath itself. The clearance sets up what would be the first time in history that a drug built on this exact mechanism gets tested in people living with MS, a milestone significant enough that it has already drawn a fresh buy rating from Wall Street analysts. 

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

For further information, please visit the company’s website at www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

DISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

• Access the video webcast here

HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here.

The presentation, featuring Walter Klemp, Chairman and Chief Executive Officer of Moleculin, provides an overview of the Company as well as recent corporate and clinical developments.

The on-demand presentation is available for viewing beginning today, September 11, 2026, at 7:00 a.m. ET, and can be accessed through the Events page on the Investors section of the Company’s website (moleculin.com). 

Management will be available on-site at the conference being held September 14-16, 2026, in New York, NY to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website. 

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML and the expectation that interim efficacy trends observed in a limited patient population will be confirmed in the full study population (the interim results presented are based on a small sample size (n=45), have not achieved statistical significance, and may not be predictive of results from the completed trial). Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

Transaction Establishes RWB in Germany and the United Kingdom, Two of Europe’s Most Important Medical Cannabis Markets

Businesses Comprising the European Platform Dispensed or Distributed More Than Twelve Tonnes of Medical Cannabis in the Twelve Months Ended July 2026¹

TORONTO, Sept. 11, 2026 (GLOBE NEWSWIRE) — Red White & Bloom Brands Inc. (CSE: RWB) (“RWB” or the “Company”) is pleased to announce that it has closed a strategic transaction with HEAL Botanicals Pharma Inc. (the “Transaction”), pursuant to which RWB now holds a controlling interest in HEAL Europe Holdings Corp. (“HEH”), a newly incorporated entity established by HEAL Botanicals Pharma Inc. for purposes of the Transaction. HEH provides RWB with an integrated European medical cannabis platform comprising operations and investments in Germany, the United Kingdom and other European markets (the “European Platform”).

The Transaction represents a significant milestone in RWB’s international growth strategy and provides the Company with exposure to established businesses spanning across pharmacy operations, pharmaceutical distribution, medical cannabis brands, patient access, fulfillment and logistics. The European Platform includes the Grünhorn group of companies (“Grünhorn”), which fulfilled approximately 290,000 medical cannabis prescriptions in the twelve months ended July 2026. Collectively, the businesses comprising the European Platform dispensed or distributed over 12 tonnes of medical cannabis in the same period².

The Transaction gives RWB a strategic foothold in two of Europe’s largest economies and key medical cannabis markets, with established operations, infrastructure, brands, patient demand and experienced teams already in place.

Significant European Market Opportunity

Germany has emerged as Europe’s largest regulated medical cannabis market, with demand accelerating following regulatory reforms introduced in 2024. Medical cannabis imports increased from approximately 73 tonnes in 2024 to approximately 205 tonnes in 2025³, representing a year-over-year increase of approximately 176%. Further, industry data indicates that Germany’s pharmacy-based medical cannabis market surpassed €1 billion in annual sales in 2025⁴.

The United Kingdom represents another significant long-term opportunity, supported by a large addressable market, importing over 30,000 kilograms of dried cannabis flower in 2025⁵, an established private medical cannabis sector and considerable potential for continued patient adoption as awareness and access expand.

Together, entering into Germany and the United Kingdom provide RWB with a strategic foothold across two of Europe’s largest economies and key medical cannabis markets, creating opportunities to leverage established operations, brands, infrastructure and expertise as the Company builds its European Platform.

Management Commentary

“Over the past several months, we have strengthened and repositioned RWB through the strategic divesture of our Florida operations and expanded our Canadian platform through the recent acquisition of Ayurcann Inc.,” said Colby De Zen, President of RWB. “With the foundation of the Company strengthened, we are now positioned to continue executing on our broader growth strategy. Closing this transaction marks an important milestone in that strategy and establishes a meaningful platform for RWB’s expansion into Europe. Germany has rapidly emerged as Europe’s largest medical cannabis market, while the United Kingdom represents another significant and growing opportunity. Importantly, we are entering these markets with established businesses, proven operating infrastructure and experienced teams already in place. We believe this gives RWB an exceptional foundation from which to scale, expand our presence and capitalize on the significant opportunities we see across the European market.”

Grünhorn – Established German Medical Cannabis Platform

Through the Transaction, RWB acquired a controlling economic interest in Grünhorn, an established participant in Germany’s rapidly expanding medical cannabis market.

Grünhorn’s operating ecosystem encompasses online medical cannabis pharmacy operations, pharmaceutical distribution and wholesale capabilities, fulfillment and logistics infrastructure and digital patient access. These complementary capabilities provide RWB with an established platform serving patients and healthcare providers throughout the German medical cannabis market.

RWB believes Grünhorn’s established market presence, infrastructure and operating capabilities provide a strong foundation from which to participate in the continued growth and development of the German market.

United Kingdom Platform

RWB’s controlling interest in Leva HEAL Limited (“Leva”) and Zerenia Clinics Limited (“Zerenia”), which operates a private medical cannabis clinic in the United Kingdom, provide the Company with exposure to the United Kingdom’s developing private medical cannabis and healthcare market.

The United Kingdom platform complements Grünhorn’s presence in Germany and provides RWB with an additional avenue for growth as patient access, physician awareness and acceptance of medical cannabis continue to develop.

Together, the German and UK businesses provide RWB with a multi-market European platform and opportunities to share expertise, infrastructure, brands and operating capabilities across jurisdictions.

Transaction Structure and Ownership

On closing, RWB acquired approximately a 62.63% controlling interest in HEH from Heal Botanicals Pharma Inc. for nominal consideration. Through HEH’s ownership structure, RWB now holds an indirect 50.1% interest in Grünhorn Gruppe AG and its underlying operating businesses, reflecting RWB’s 62.63% acquired equity interest in HEH and HEH’s 80% equity interest in Grünhorn Gruppe AG.

RWB also acquired a direct 29.82% interest in both Zerenia and Leva with Heal Botanicals Pharma Inc. continuing to hold a 19.93% direct interest respectively. Combined with RWB’s indirect interest held through HEH, which holds 50.25% of Zerenia and Leva, RWB holds an effective interest of approximately 61.3% in each of Leva and Zerenia.

The Transaction therefore provides RWB with controlling economic interests in the principal businesses comprising the European Platform.

Senior Secured Credit Facility

In order to support the European Platform and its continued growth, RWB has committed to provide HEH with a senior secured credit facility of up to a maximum principal amount of C$25 million (the “Facility”), of which an aggregate of C$18.7 million has been advanced to date.

The principal terms of the Facility include:

• a maximum committed principal amount of C$25 million, of which C$18.7 million has been advanced to date (C$15.7 million advanced as of June 30, 2026, with an additional C$3 million advanced on August 4, 2026);
• interest at a fixed rate of 12% per annum;
• interest during the first six months following closing (“the PIK Period”) will be capitalized and added to the outstanding principal;
• a three-year term maturing September 10, 2029, with interest following the PIK Period payable from HEH’s cash flow in accordance with the terms set out in the definitive financing documents; and
• a senior secured position over the assets of HEH, supported by guarantees and/or security from the relevant operating subsidiaries, in each case under the applicable financing and security documents.

In addition, approximately C$2.5 million of existing shareholder loans and intercompany balances will remain outstanding and be carried into HEH.

The combination of controlling equity ownership and senior secured financing provides RWB with participation in the long-term growth of the European Platform while preserving the protections and economics associated with its secured lending position.

About Red White & Bloom Brands Inc.

Red White & Bloom Brands Inc. is a publicly listed multi-jurisdictional cannabis company with operations and investments in regulated markets. The Company is focused on building and acquiring leading cannabis brands and operating assets while pursuing disciplined growth through strategic acquisitions, investments and partnerships. The Company is listed on the Canadian Securities Exchange under the symbol “RWB”.

For further information, please contact:

Edoardo Mattei, Chief Financial Officer
Red White & Bloom Brands Inc.
Email: ir@redwhitebloom.com

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Visit us on the web: https://www.redwhitebloom.com/

Follow us on social media:

X: @rwbbrands
Facebook: @redwhitebloombrands
Instagram: @redwhitebloombrands

FORWARD-LOOKING INFORMATION

Certain information contained in this news release may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking information is often identified by words such as “plans,” “expects,” “may,” “should,” “could,” “will,” “intends,” “anticipates,” “believes,” “estimates,” and “forecasts,” or variations or negative forms of such words and phrases, as well as terms such as “pro forma” and “scheduled,” and other similar expressions that refer to future events or outcomes.

Forward-looking information in this release include, without limitation, statements relating to the availability and funding of future advances under the Facility; the anticipated benefits of the Transaction; the growth and development of the German and United Kingdom medical cannabis markets; the future operations of HEH and its subsidiaries and investments; RWB’s expansion within the European medical cannabis market; potential collaboration among the businesses comprising the European Platform; RWB’s ability to fund further advances under the Facility; the recoverability of amounts advanced to HEH; and other statements that are not historical facts. Such forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied. Material risk factors include, without limitation: the risk that HEH is unable to repay amounts advanced under the Facility and that the Company is required to record an impairment or expected credit loss on its loan receivable; the Company’s own liquidity position and its ability to fund further advances, as described in the going concern disclosure in the Company’s most recent annual financial statements and management’s discussion and analysis; the risk that the guarantees and security granted in favour of the Company prove unenforceable in the relevant foreign jurisdictions; changes to German law and regulation governing telemedicine prescribing, mail-order dispensing and the importation of medical cannabis; changes to United Kingdom licensing and prescribing requirements; the fact that the majority of the HEH entities are unaudited and that historical operating metrics have not been independently verified; integration, foreign exchange, minority shareholder; shareholder loans, and governance risks; and the risk that the anticipated benefits of the Transaction are not realized.

In making the forward-looking information contained in this news release, the Company has applied a number of material factors and assumptions, including that all required consents, approvals and acceptances will be maintained; HEH and its businesses comprising the European Platform will operate substantially as anticipated; the European medical cannabis markets will continue to develop and expand; sufficient cash flow or financing will be available to satisfy obligations as they become due; the guarantees and security granted in favour of the Company will remain valid and enforceable; and there will be no material adverse change in the regulatory or business environment in the jurisdictions in which HEH and its subsidiaries carry on business.

The prescription and dispensing volumes disclosed in this news release are based on information provided by the businesses comprising the European Platform. These figures are unaudited and have not been independently verified. In presenting these figures, the Company has assumed that the underlying information is accurate and complete, that the figures are representative of ordinary-course operations and that the figures are presented on a 100% basis without adjustment for RWB’s proportionate economic interests in the applicable businesses.

Additional risks and uncertainties affecting the Company are described in the Company’s most recently filed management’s discussion and analysis and other continuous disclosure documents, available under the Company’s profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned not to place undue reliance on forward-looking information. The forward-looking information contained in this news release is made as of the date of this news release, and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

^{____________________________________
1} Unaudited; presented on a 100% Basis; not adjusted for RWB’s economic interest post-close
² Unaudited; presented on a 100% basis and not adjusted for RWB’s economic interest post-close
³ https://www.bfarm.de/SharedDocs/Bilder/DE/Diagramme/Bundesopiumstelle/Einfuhren_med_Cannabisblueten.jpg
⁴ https://cannamonitor.com/germany-imports-201-tonnes-of-medical-cannabis-in-2025/
⁵ https://businessofcannabis.com/uk-medical-cannabis-prescriptions-hit-1-7-million-in-2025-as-acmd-review-approaches

Initial contract includes 100 Low-Cost Tactical ISR UAS systems, with options for Canadian Armed Forces to acquire up to 4,900 additional systems

Calgary, Alberta, Sept. 11, 2026 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading developer of drone solutions and systems, today announced that it has been awarded a five-year contract by the Government of Canada to provide Low-Cost Tactical Intelligence, Surveillance and Reconnaissance (“ISR”) Uncrewed Aircraft Systems (“UAS”) to the Canadian Armed Forces (“CAF”).

The initial contract includes a firm commitment for 100 Low-Cost Tactical ISR UAS systems, together with associated ground control stations, payloads, data links, support equipment, documentation, spare parts and training. Contracted pricing for the systems is commercially sensitive.

Under the five-year agreement, the Government of Canada has retained the right, at its sole discretion, to order up to an additional 4,900 UAS systems. If all available options were exercised, the total number of UAS systems supplied under the agreement to the Government of Canada would be 5,000. The contractual option for the additional 4,900 UAS systems has an aggregate value of approximately C$24.25 million if exercised in full. Any exercise of those options would require the appropriate written contract authorization or amendment.

The contract also includes initial cadre training for CAF personnel and provides Canada with options for additional training. Draganfly will support the program across system delivery, training, sustainment, spare parts, documentation, software and firmware support.

Draganfly was recently accepted as a qualified supplier in all five categories of Canada’s Defence Drone Initiative (“DDI”) Marketplace. This contract represents a subsequent procurement by the Government of Canada under the initiative and advances Draganfly’s participation in Canada’s expanding domestic defence and uncrewed systems ecosystem.

“This award is an important milestone for Draganfly and a meaningful opportunity to support the Canadian Armed Forces with systems designed to be fielded, supported and scaled in response to real operational requirements,” said Cameron Chell, President and CEO of Draganfly. “Canada is moving quickly to strengthen its sovereign defence capabilities and domestic industrial base. We are proud that Draganfly’s technology and team have been selected to contribute to that effort and look forward to delivering these systems into the hands of Canadian operators.”

Canada’s Defence Drone Initiative is intended to accelerate access to Canadian-developed uncrewed and autonomous capabilities while strengthening the country’s domestic defence industrial base. Low-cost tactical ISR drones are one of the initiative’s initial priority areas, with a focus on secure and affordable systems that can be widely deployed, field-tested and adapted based on operator requirements.

About Draganfly

Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8) is a leader in cutting-edge drone solutions and software that are transforming industries and serving stakeholders globally. Recognized for innovation and excellence for over 25 years, Draganfly delivers award-winning technology to the public safety, civil, military, agriculture, industrial inspection, security, mapping, and surveying markets. The Company is driven by passion, ingenuity, and a mission to provide efficient solutions and first-class services to customers worldwide, saving time, money, and lives.

For more information, visit www.draganfly.com.

For investor details, visit:
NASDAQ (DPRO)
CSE (DPRO)
FSE (3U8)

Media Contact
Erika Racicot
Email: media@draganfly.com

Company Contact
Cameron Chell
Chief Executive Officer
(306) 955-9907
Email: info@draganfly.com

Forward-Looking Statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian and U.S. securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements in this release include, but are not limited to: the aggregate number of UAS systems CAF will order based on exercises of options; that Draganfly expand will role in Canada’s Defence Industrial Strategy. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including but not limited to: statements in respect of Draganfly’s partnerships, capabilities, expertise, and financial condition; the successful integration of technology, the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of cost estimates and the potential for unexpected costs and expenses, currency fluctuations; regulatory restrictions, liability, competition, loss of key employees and other related risks and uncertainties disclosed under the heading “Risk Factors“ in the Company’s most recent filings filed with securities regulators in Canada on the SEDAR+ website at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on the EDGAR website at www.sec.gov.

The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents managements’ best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

WARRENVILLE, Ill., Sept. 11, 2026 (GLOBE NEWSWIRE) — Fuel Tech, Inc. (NASDAQ: FTEK), a technology company using advanced engineering processes to provide emissions control systems and water treatment technologies in utility and industrial applications, today announced the award of multiple air pollution control (APC) contracts valued at approximately $2.8 million for utility and industrial customers.

An order was secured for a urea reagent delivery system for a new U.S. utility customer adding new natural gas-fired turbines and reciprocating engines as part of a power plant expansion. The scope is to supply the urea reagent delivery systems to support Selective Catalytic Reduction (SCR) systems to reduce nitrogen oxide (NO_x) emissions to meet the site requirements. The urea system eliminates the hazards associated with the transport, storage and handling of anhydrous or aqueous ammonia. Fuel Tech will commence engineering work immediately with equipment delivery expected in the third quarter of 2027.  

Two separate awards were received for electrostatic precipitator (ESP) performance modeling services from new domestic and international customers. The ESP modeling incorporates a suite of interdependent computer models into a Numerical Electrostatic Precipitation (NEP) model, which quickly and economically identifies the available upgrade options that can help improve ESP performance and achieve compliance with new and emerging particulate environmental regulations.  Both modeling contracts are expected to be completed in the fourth quarter of 2026.

A contract was also secured from a repeat domestic customer to demonstrate Selective Non-Catalytic Reduction (SNCR) technology on a waste incinerator unit. Fuel Tech’s SNCR technology is a proven solution for industrial combustion unit owners looking to comply with more stringent NO_x control requirements. The demonstration is scheduled for the third quarter of 2026 and, subject to a successful outcome, permanent equipment orders could be secured in the fourth quarter of 2026.

“We are pleased to announce these contract awards and upcoming demonstration that support the needs of our diverse customer base. These orders bring us to $15 million in announced bookings year-to-date, and an effective backlog of $20 million. We are continuing to actively pursue additional APC contracts that are likely to be awarded in the next 60-90 days. We continue to see growth in 2026 with our core products and services as we look towards future strategic growth opportunities,” said Ramesh Nuggihalli, President and CEO.

About Fuel Tech

Fuel Tech develops and commercializes state-of-the-art proprietary technologies for air pollution control, process optimization, water treatment, and advanced engineering services. These technologies enable customers to operate in a cost-effective and environmentally sustainable manner. Fuel Tech is a leader in nitrogen oxide (NOx) reduction and particulate control technologies, and its solutions have been installed on over 2,100 utility, industrial and municipal units worldwide. The Company’s chemical technologies improve the efficiency, reliability, fuel flexibility, boiler heat rate, and environmental status of combustion units by controlling slagging, fouling, corrosion and opacity. This includes Fuel Tech’s advanced TIFI^® Targeted In-Furnace Injection™ technology which offers an innovative solution to fireside treatment on boilers using coal, oil or biomass. Water treatment technologies include DGI^® Dissolved Gas Infusion Systems which utilize a patented saturator and a patent-pending channel injector to deliver supersaturated oxygen solutions and other gas-water combinations to target process applications or environmental issues. This infusion process has a variety of applications in the water and wastewater industries, including remediation, aeration, biological treatment and wastewater odor management. Many of Fuel Tech’s products and services rely heavily on the Company’s exceptional Computational Fluid Dynamics modeling capabilities, which are enhanced by internally developed, high-end visualization software. For more information, visit Fuel Tech’s web site at ftek.com.

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” as defined in Section 21E of the Securities Exchange Act of 1934, as amended, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and reflect Fuel Tech’s current expectations regarding future growth, results of operations, cash flows, performance and business prospects, and opportunities, as well as assumptions made by, and information currently available to, our management. Fuel Tech has tried to identify forward-looking statements by using words such as “anticipate,” “believe,” “plan,” “expect,” “estimate,” “intend,” “will,” and similar expressions, but these words are not the exclusive means of identifying forward-looking statements. These statements are based on information currently available to Fuel Tech and are subject to various risks, uncertainties, and other factors, including, but not limited to, those discussed in Fuel Tech’s Annual Report on Form 10-K in Item 1A under the caption “Risk Factors,” and subsequent filings under the Securities Exchange Act of 1934, as amended, which could cause Fuel Tech’s actual growth, results of operations, financial condition, cash flows, performance and business prospects and opportunities to differ materially from those expressed in, or implied by, these statements. Fuel Tech undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements contained herein to reflect future events, developments, or changed circumstances or for any other reason. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including those detailed in Fuel Tech’s filings with the Securities and Exchange Commission.

CONTACT:    Devin Sullivan
                      Managing Director
                      The Equity Group Inc.
                      devin.sullivan@theequitygroup.com

Mandeep Chawla named to newly created role of Group President, Global Markets;
Todd Ankenmann appointed to Chief Financial Officer

TORONTO, Sept. 11, 2026 (GLOBE NEWSWIRE) — Celestica Inc. (NYSE, TSX: CLS), a global leader in data center infrastructure and advanced technology solutions, today announced executive leadership appointments to align with the company’s strong growth trajectory and position the business for sustainable, multi-year growth. Effective October 1, 2026, Mandeep Chawla will assume the newly created role of Group President, Global Markets, and Todd Ankenmann will succeed him as Chief Financial Officer (CFO).

In the new role of Group President, Global Markets, Chawla will oversee the company’s overarching commercial execution and global market expansion. This structure is designed to drive operational velocity, scale the business effectively and capture accelerating demand across Celestica’s end markets.

Chawla has served as Celestica’s CFO since 2017, playing a critical role in driving the company’s financial health, strategic transformation, and long-term performance. Prior to joining Celestica in 2010, Chawla spent nearly a decade at General Electric (GE), followed by senior leadership roles across the engineering and life sciences sectors.

“Celestica is experiencing unprecedented growth, and as we look to the future, we are evolving our leadership structure to ensure we can scale effectively and continue delivering exceptional value to our customers and shareholders,” said Rob Mionis, Chairman and Chief Executive Officer, Celestica. “Mandeep has been an outstanding CFO and a core contributor to our strategic vision. His deep understanding of our business, combined with his exceptional commercial acumen, makes him the ideal leader to step into this crucial new role to drive our next chapter of growth.”

Succeeding Chawla as CFO is Todd Ankenmann, who brings a wealth of institutional knowledge and financial expertise to the executive team. Ankenmann joined Celestica in 2018 and currently serves as Senior Vice President, Finance, where he plays a pivotal role in strategic planning, financial reporting, and commercial execution. Before joining Celestica, Ankenmann spent over a decade in senior finance leadership roles at GE.

“With his deep understanding of our business model, rigorous financial management, and proven track record across our ATS and CCS businesses, Todd is uniquely positioned for a seamless transition to Chief Financial Officer,” said Mionis. “Together, these appointments optimize our executive team to deliver on our long-term growth objectives.”

About Celestica
Celestica is a technology leader dedicated to driving customer success and market advancements. With deep expertise in design, engineering, manufacturing, supply chain, and platform solutions, Celestica enables critical data center infrastructure for AI, cloud and hybrid cloud, and advances technologies in high-growth markets. With a talented team and a strategic global network, Celestica helps its customers achieve competitive advantages. For more information on Celestica, visit www.celestica.com. Our securities filings can be accessed at www.sedarplus.ca and www.sec.gov.

Cautionary Note Regarding Forward-Looking Statements
Statements in this press release relating to Celestica’s future plans, expectations, beliefs, and intentions are “forward-looking statements” and are subject to material risks, uncertainties, and assumptions. Those statements may include statements related to strong growth trajectory and sustainable, multi-year growth, and expected benefits of leadership appointments, including driving operational velocity, scaling the business effectively and capturing accelerating demand across end markets, all of which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, and Canadian securities laws. Forward-looking statements are commonly identified by words such as “would,” “may,” “expects,” “believes,” “designed to” “intends,” “position for” and other terms with similar meaning. Investors are cautioned that the forward-looking statements in this press release are based on current beliefs, assumptions and expectations, speak only as of the date of this press release and involve risks and uncertainties that could cause actual results to differ materially from current expectations. Such statements are subject to certain known and unknown risks and uncertainties, many of which are difficult to predict and are generally beyond Celestica’s control, that could cause actual results and other future events to differ materially from those expressed in, or implied or projected by, the forward-looking information. Investors are urged to review in detail the risks, uncertainties, and assumptions contained in Celestica’s Securities and Exchange Commission (SEC) filings, including Celestica’s most recent reports on Form 10-K, Form 10-Q, Current Reports on Form 8-K and other documents filed with, or furnished to, the SEC, and the Canadian Securities Administrators. These filings are available on the SEC’s website, and www.sedarplus.ca or on Celestica’s website at https://corporate.celestica.com/sec-filings. Celestica undertakes no duty to update any statement in light of new information or future events or otherwise, except as expressly required by applicable law.

Celestica Contacts:
Celestica Global Communications
(416) 448-2200
media@celestica.com

Celestica Investor Relations
clsir@celestica.com

Company begins trading under HLSQ; completes rebrand to become an integrated platform serving digital infrastructure, energy, critical infrastructure and homeland security

NETANYA, Israel, Sept. 11, 2026 (GLOBE NEWSWIRE) — Tessera Defense and Homeland Security Inc. (NYSE American: HLSQ), formerly BiomX Inc. (NYSE American: PHGE) (“Tessera” or the “Company”), today announced that its corporate name and ticker symbol changes are now effective, completing its rebrand as a physical security technology platform.

The Company’s common stock will begin trading under the symbol “HLSQ” on the NYSE American at the market open on Friday September 11, 2026. Trading will continue without interruption, and no action is required by stockholders in connection with the name and symbol change.

The rebrand comes as governments and organizations face increasing pressure to protect the infrastructure, systems and sites upon which modern society depends. Recent attacks and suspected acts of sabotage affecting power infrastructure across Europe, incidents involving energy and transportation infrastructure in Germany, and the heightened protection of critical infrastructure across Poland and the Baltic states have placed physical security firmly on the international agenda.

Tessera provides a unified security platform that connects cameras, sensors, detection technologies, artificial intelligence and other systems, and offers solution design as well as advisory capabilities to address customers’ evolving physical security needs. The platform is designed to detect threats, understand events as they unfold and coordinate response in real time, supporting security teams, security managers and chief security officers across complex environments. The Company serves customers across homeland security, critical infrastructure, as well as enterprise organizations seeking advanced physical security capabilities.

Modern threats often cross traditional security boundaries, while protective systems remain disconnected, offering only isolated alerts. By converting fragmented data into unified, real-time insights, Tessera’s solution, tailored to each site’s specific needs, enables security teams to see a site as a whole rather than as a series of separate alerts. Tessera also offers security experts to audit sites so the platform can be used to its full potential and enable security teams to have full situational awareness of their environment.

“The name Tessera reflects both how our platform works and how we’re building the Company,” said Michael Oster, CEO of Tessera. “A tessera is an individual tile that becomes part of a larger mosaic. In the same way, we’re bringing together complementary technologies across detection, intelligence and response to create one integrated security platform. As threats become more complex, national security and infrastructure protection personnel need to understand what is happening and coordinate action faster and more accurately. Tessera is designed to help them make quicker, better-informed decisions to protect people and keep critical systems and sites secure.” 

Tessera’s capabilities include the AI-powered security intelligence technology of its subsidiary Zorronet and the LADAR-based detection systems of its subsidiary DFSL, supporting an integrated approach to advanced sensing, real-time intelligence and autonomous response.

The name change takes effect on the 25th anniversary of the September 11 attacks, a date the Company selected in remembrance of all those who were lost, including the hundreds of first responders who gave their lives while working to save others.  

About Tessera Defense and Homeland Security Inc. (Formerly BiomX Inc.)

Tessera Defense and Homeland Security Inc. (NYSE American: HLSQ) is a physical security technology company providing integrated, bespoke security solutions that connect detection, intelligence and response across complex security environments. The Tessera platform integrates cameras, sensors, detection technologies, AI and other security infrastructure to identify threats, understand events and coordinate response in real time. Tessera provides the technology, hardware and implementation expertise needed to tailor security solutions to the specific requirements of each site, helping customers deploy and optimize integrated security systems across critical infrastructure, energy, digital infrastructure and homeland security applications. 

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, platform, capabilities, portfolio, target markets, and the anticipated benefits of bringing complementary technologies together within an integrated security platform. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties, including risks related to the Company’s ability to execute its strategy, integrate and commercialize its technologies, achieve market acceptance, and those risks described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, as supplemented by the Form 10-K/A filed with the SEC on April 30, 2026, the Company’s Current Report on Form 8-K filed with the SEC on May 5, 2026, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Actual results may differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statement, except as required by law. 

Media Contact: 

Yair Ohayon 
IR & Communication Manager
Yairo@thlsq.ai